Dafinchi AI

OFG

Financial Services

Capital ratios remained strong with CET1 at 13.99% and tangible common equity ratio at 10.20%.
Core revenues totaled $182 million, with total interest income of $194 million and interest expense of $42 million.
Net charge-offs were $13 million, down $7.6 million sequentially, with a net charge-off rate of 0.64%.
Net interest margin was 5.31%, slightly down from 5.42%, impacted by increased liquidity and wholesale funding.
Noninterest expenses were $94.8 million, in line with guidance of $95-96 million for 2025.
Record assets exceeded $12 billion and loans surpassed $8 billion, with strong loan origination and core deposit flows.
Return on average assets was 1.73% and return on average tangible common equity was 17%.
Second quarter earnings per share diluted was $1.15, a 6.5% increase year-over-year, driven by a 1.5% increase in total core revenue.
Tangible book value per share was $27.67, and efficiency ratio was 52%.

APLE

Financial Services

Adjusted EBITDAre was approximately $133 million for Q2 2025, down about 6% year-over-year.
Adjusted hotel EBITDA for comparable hotels was $142 million in Q2 2025, down approximately 5% year-over-year.
Comparable hotels total revenue was $380 million for Q2 2025, slightly down from Q2 2024.
MFFO for Q2 2025 was approximately $112 million or $0.47 per share, down 6% on a per share basis compared to Q2 2024.
Q2 2025 comparable hotels RevPAR was $129, down 1.7% compared to Q2 2024, with ADR at $164 and occupancy at 79%.
Total hotel expenses increased by 2.8% for Q2 2025, with payroll per occupied room up 3% to $39.
Year-to-date through June, comparable hotels RevPAR was $120, down 1.1%, ADR was $160 (up 0.4%), and occupancy was 75%.

RPRX

Financial Services

Capital deployment totaled $595 million, including $250 million upfront for Revolution Medicines and $200 million milestone payment related to Adstiladrin.
Cash and equivalents stood at $632 million with investment-grade debt of $8.2 billion and leverage at approximately 3x total debt to EBITDA.
Net interest was a positive $8 million due to timing of interest payments and cash interest received.
Operating and professional costs were 12.9% of Portfolio Receipts including a $35 million one-time internalization expense; excluding this, costs were just over 8%.
Portfolio cash flow (adjusted EBITDA less net interest paid) was $641 million, representing an 88% margin.
Royalty Pharma delivered 20% growth in Portfolio Receipts to $727 million in Q2 2025, exceeding guidance of $700 million to $725 million.
Royalty Receipts grew 11% to $672 million, contributing to 11% growth in the first half of 2025.
Weighted average share count declined by 35 million shares due to share buybacks.

Earnings Feed